Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Aug 11 2022

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Prochlorperazine Maleate Tablets. The tablets are indicated for treating various mental health conditions and controlling severe nausea and vomiting. The manufacturing will take place at the company's facility in Ahmedabad SEZ, India.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Zydus Lifesciences Limited on 6ix

In the deck

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases